Keywords: پاسخ پایدار ویروسی; Liver Transplantation; HCC; Cholabgiocarcinoma; Machine Perfusion; Hepatitis C; AASLD; American Association for the Study of Liver Diseases; BAR; balance of risk; D-MELD; donor age à recipient Model of End-Stage Liver Disease; DCC; distal cholangiocarci
مقالات ISI پاسخ پایدار ویروسی (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: پاسخ پایدار ویروسی; Liver Cirrhosis; Serum Markers; Imaging; ARFI; SWE; TE; Magnetic Resonance Imaging; Liver Stiffness; Elastography; Shear Wave; NAFLD Fibrosis Score; BARD; APRI; aspartate aminotransferase-to-platelet ratio; ARFI; acoustic radiation force impulse; AST/ALT;
Keywords: پاسخ پایدار ویروسی; DAA; direct-acting antiviral; HCV; hepatitis C virus; SVR; sustained virologic response; PR; peginterferon plus ribavirin; EPO; erythropoietin; BMI; body mass index; Hb; hemoglobin; ROC; receiver-operator characteristic; CI; confidence interval; OR; odds
Keywords: پاسخ پایدار ویروسی; SNPs; Single nucleotide polymorphisms; IFNL3; interferon lambda 3; SVR; sustained virologic response; HCV-2/3; Hepatitis C virus genotype 2 and 3; RVR; rapid virological response; OR; odds ratio; PegIFNα/RBV; pegylated interferon-alpha and ribavirin; CHC
Keywords: پاسخ پایدار ویروسی; direct-acting antivirals; HCV; HIV; managed care organizations; sustained virologic response; underserved population
The association of CCL3 and CCL4 polymorphisms with HCV clearance in Chinese Han population
Keywords: پاسخ پایدار ویروسی; HCV; hepatitis C virus; SVR; sustained virologic response; pegIFN-α; pegylated interferon-α; RBV; ribavirin; SNPs; single nucleotide polymorphisms; WT; wild-type; GLU; glucose; GWAS; genome-wide association study; MIP-1α; macrophage inflammatory protei
Evaluation of TRIM5 and TRIM22 polymorphisms on treatment responses in Iranian patients with chronic hepatitis C virus infection
Keywords: پاسخ پایدار ویروسی; HCV; hepatitis C virus; CHC; chronic HCV; HCC; hepatocellular cancer; SVR; sustained virologic response; TRIM; tripartite motif; pegIFN-α/RBV; pegylated interferon-α and ribavirin; DDAs; direct-acting antivirals; RVR; rapid virologic response; cEVR; com
Is there sufficient evidence to repeal three decades of clinical research on chronic hepatitis C?
Keywords: پاسخ پایدار ویروسی; Direct-acting antivirals for chronic hepatitis C; Evidence-based medicine; Hepatitis C; Hepatocellular carcinoma; Meta-analysis; Observational study; Outcome research; Randomized controlled study; Sustained virologic response;
No Difference in Effectiveness of 8 vs 12 Weeks of Ledipasvir and Sofosbuvir for Treatment of Hepatitis C in Black Patients
Keywords: پاسخ پایدار ویروسی; Direct-acting Antiviral Agents; Sustained Virologic Response; Race; Effectiveness; AASLD; American Association for the Study of Liver Diseases; CI; confidence interval; HCV; hepatitis C virus; HIV; human immunodeficiency virus; ICD; International Classifi
Efficacy of Sofosbuvir and Velpatasvir, With and Without Ribavirin, in Patients With Hepatitis C Virus Genotype 3 Infection and Cirrhosis
Keywords: پاسخ پایدار ویروسی; Direct-Acting Antiviral Agent; Outcome; Drug Resistance; AE; adverse event; HCV; hepatitis C virus; HIV; human immunodeficiency virus; NS5A; nonstructural protein 5A; NS5B; nonstructural protein 5B; RAS; resistance-associated substitution; SAE; serious ad
Sofosbuvir Based Regimen in Management of Hepatitis C for Patients With End Stage Renal Disease on Hemodialysis: A Single Center Experience from India
Keywords: پاسخ پایدار ویروسی; CHC; chronic hepatitis C; DAA; direct-acting antivirals; ESRD; end stage renal disease; HCV; hepatitis C virus; SVR; sustained virologic response; hepatitis C; direct-antiviral agents; end-stage renal disease; liver cirrhosis;
Cost Effectiveness of Pre- vs Post-Liver Transplant Hepatitis C Treatment With Direct-Acting Antivirals
Keywords: پاسخ پایدار ویروسی; Simulation Model; Sofosbuvir; Health Economics; DAA; oral direct-acting antiviral; HCV; hepatitis C virus; ICER; incremental cost-effectiveness ratio; LT; liver transplantation; MELD; Model for End-stage Liver Disease; QALY; quality-adjusted life year; SV
HCV phylogenetic signature and prevalence of pretreatment NS5A and NS5B NI-Resistance associated substitutions in HCV-Infected patients in Mainland China
Keywords: پاسخ پایدار ویروسی; Direct-acting antivirals; Resistance associated substitutions; DAAs; direct-acting antiviral agents; NI; nucleoside/nucleotide inhibitor; PI; protease inhibitor; RAS; resistance-associated substitution; SVR; sustained virologic response; SVR12; sustained
Incidence of Hepatocellular Carcinoma in Patients With HCV-Associated Cirrhosis Treated With Direct-Acting Antiviral Agents
Keywords: پاسخ پایدار ویروسی; RESIST-HCV; Liver Cancer Risk; Reduction; Sofosbuvir; BCLC; Barcelona Clinic Liver Cancer; CI; confidence interval; DAAs; direct-antiviral agents; EGS; esophageal gastroscopy; EV; esophageal varices; HCC; hepatocellular carcinoma; HCV; hepatitis C virus;
Patterns of Resistance-Associated Substitutions in Patients With Chronic HCV Infection Following Treatment With Direct-Acting Antivirals
Keywords: پاسخ پایدار ویروسی; HCV; RASs; DAA; Virologic Treatment Failure; DAA; direct-acting antiviral; DCV; daclatasvir; EOT; end of treatment; GT; genotype; HCV; hepatitis C virus; LDV; ledipasvir; NS; nonstructural protein; PCR; polymerase chain reaction; PEG IFN; pegylated interf
Efficacy and Safety of Sofosbuvir-Based Direct Acting Antivirals for Hepatitis C in Septuagenarians and Octogenarians
Keywords: پاسخ پایدار ویروسی; DAA; direct acting antiviral; HCV; hepatitis C virus; SVR; sustained virologic response; direct acting antivirals; elderly; hepatitis C;
Antiviral response and resistance analysis of treatment-naïve HCV infected patients receiving multiple doses of the NS3 protease inhibitor GS-9256
Keywords: پاسخ پایدار ویروسی; Phase 1 monotherapy study; Drug resistance profile; Genotype 1; Sequencing; DAAs; Direct acting antivirals; PI; protease inhibitor; RAS; resistance associated substitution; SVR; sustained virologic response;
A profiling study of a newly developed HCVcc strain PR63cc's sensitivity to direct-acting antivirals
Keywords: پاسخ پایدار ویروسی; HCV; DAA; Drug resistance; HCVcc; Resistance-associated variants; HCV; Hepatitis C virus; DAA; Direct-acting antiviral; RAV; Resistance-associated variant; SVR; Sustained virologic response; HCVcc; Hepatitis C virus cell culture system; ORF; Open reading
Efficacy and tolerability of an IFN-free regimen with DCV/ASV for elderly patients infected with HCV genotype 1B
Keywords: پاسخ پایدار ویروسی; Aged patients; Chronic hepatitis C; Direct-acting antiviral; Sustained virologic response; Tolerability;
The impact of genetic variation in IL28B, IFNL4 and HLA genes on treatment responses against chronic hepatitis C virus infection
Keywords: پاسخ پایدار ویروسی; Interleukin-28B; Interferon lambda 4; Human leukocyte antigen; Rapid virologic response; Complete early virologic response; Sustained virologic response;
Effectiveness and Tolerability of Direct Acting Antiviral Therapy for Hepatitis C in a Real World Elderly Cohort
Keywords: پاسخ پایدار ویروسی; DAA; direct acting antiviral; HCV; hepatitis C virus; LDV; ledipasvir; RBV; ribavirin; SMV; simeprevir; SOF; sofosbuvir; SVR12; sustained virologic response;
Effectiveness of hepatitis C antiviral treatment in a USA cohort of veteran patients with hepatocellular carcinoma
Keywords: پاسخ پایدار ویروسی; Ledipasvir/sofosbuvir; Paritaprevir/ritonavir/ombitasvir and dasabuvir; Liver transplant; Sustained virologic response;
Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosis
Keywords: پاسخ پایدار ویروسی; Direct-acting antiviral; Pangenotypic; ABT-493; ABT-530; SURVEYOR; D-alanine transaminase; Sustained virologic response; Hepatitis C, chronic; Liver cirrhosis; Interferons; Genotype;
NS5A resistance-associated substitutions in patients with genotype 1 hepatitis C virus: Prevalence and effect on treatment outcome
Keywords: پاسخ پایدار ویروسی; NS5A RAS; HCV genotype 1; Ledipasvir; Sofosbuvir; Sustained virologic response; Genotype; Treatment outcome;
Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials
Keywords: پاسخ پایدار ویروسی; Direct-Acting Antiviral Agent; Shortened Duration Therapy; Clinical Trial; Comparison; CI; confidence interval; DAA; direct-acting antiviral agent; HCV; hepatitis C virus; SVR; sustained virologic response;
Vitamin D in liver disease: Current evidence and potential directions
Keywords: پاسخ پایدار ویروسی; 1,25D; 1,25(OH)2 vitamin D; 25D; 25(OH) vitamin D; ACR; acute cellular rejection; CKD; chronic kidney disease; CYP; Cytochrome P450; HBV; hepatitis B virus; HCV; hepatitis C virus; HCC; hepatocellular cancer; HSC; hepatic stellate cell; IL; Interleukin; I
Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection: Results from a Spanish real-world cohort
Keywords: پاسخ پایدار ویروسی; Hepatitis C, Chronic; Genotype 1; Ombitasvir; Paritaprevir; Ritonavir; Dasabuvir; Ledipasvir; Sofosbuvir; Real-world; Antiviral agents; Sustained virologic response; Randomized controlled trials;
Hepatitis C
Keywords: پاسخ پایدار ویروسی; Chronic hepatitis C; Hepatitis C treatment; Hepatitis C virus; Antiviral therapies; Direct-Acting antivirals; Sustained virologic response;
Hepatitis due to Reactivation of Hepatitis B Virus in Endemic Areas Among Patients With Hepatitis C Treated With Direct-acting Antiviral Agents
Keywords: پاسخ پایدار ویروسی; Therapy; Risk Factor; Coinfection; Prognostic Factor; CHC; chronic hepatitis C; DAA; direct-acting antiviral agent; HBeAg; hepatitis B e antigen; HBsAg; hepatitis B surface antigen; HBV; hepatitis B virus; HCC; hepatocellular carcinoma; HCV; hepatitis C v
Hepatitis B and C
Keywords: پاسخ پایدار ویروسی; Hepatitis B; Hepatitis C; Sustained virologic response; Pegylated interferon; Direct-acting antiviral agents; Spontaneous viral clearance;
Virologic, Clinical, and Immune Response Outcomes of Patients With Hepatitis C Virus-Associated Cryoglobulinemia Treated With Direct-Acting Antivirals
Keywords: پاسخ پایدار ویروسی; Cryoglobulinemic Vasculitis; Hepatitis C; DAA; Antiviral Therapy; ACC; asymptomatic circulating cryoglobulins; BVAS.v3; Birmingham Vasculitis Activity Score version 3; C4; complement 4 fraction; CH50; 50% hemolytic complement activity; CV; cryoglobulinemi
Biopsy Specimens From Allograft Liver Contain Histologic Features of Hepatitis C Virus Infection After Virus Eradication
Keywords: پاسخ پایدار ویروسی; Pathology; Recurrence; Tissue Damage; DAA Therapy; ACR; acute cellular rejection; CMV; cytomegalovirus; DAA; direct acting antiviral; EBV; Epstein-Barr virus; FFPE; formalin-fixed, paraffin-embedded; HCV; hepatitis C virus; PCR; polymerase chain reactio
Efficacy and Safety of Sofosbuvir Plus Daclatasvir for Treatment of HCV-Associated Cryoglobulinemia Vasculitis
Keywords: پاسخ پایدار ویروسی; DAA; Cryoglobulinemia Vasculitis; Autoimmunity; Treg Cell; CryoVas; cryoglobulinemia vasculitis; DAA; direct-acting antiviral; HCV; hepatitis C virus; IFN; interferon; SVR; sustained virologic response;
Effect of IL15 rs10833 and SCARB1 rs10846744 on virologic responses in chronic hepatitis C patients treated with pegylated interferon-α and ribavirin
Keywords: پاسخ پایدار ویروسی; HCV; hepatitis C virus; CHC; chronic HCV; HCC; hepatocellular cancer; SVR; sustained virologic response; SCARBI; scavenger receptor type B class I; IL-15; interleukin-15; DDAs; direct-acting antivirals; RVR; rapid virologic response; cEVR; completely earl
American Gastroenterological Association Institute Technical Review on the Role of Elastography in Chronic Liver Diseases
Keywords: پاسخ پایدار ویروسی; Fibrosis; Noninvasive Imaging; Chronic Liver Diseases; Guidelines; APRI; aspartate aminotransferase to platelet ratio index; AUROC; area under the receiver operating characteristic; CI; confidence interval; CLD; chronic liver disease; EGD; esophagogastrod
Eradication of Hepatitis C Virus Infection in Patients With Cirrhosis Reduces Risk of Liver and Non-Liver Complications
Keywords: پاسخ پایدار ویروسی; ANRS CirVir; HCV Clearance; Direct Antivirals; Prognosis; AFP; α-fetoprotein; ANRS CO12 CirVir; Agence Nationale pour la Recherche sur le SIDA et les hépatites virales cohort 12 viral cirrhosis; BI; bacterial infection; CumI; cumulated incidence; DAA; d
Identification of the Best Direct-Acting Antiviral Regimen for Patients With Hepatitis C Virus Genotype 3 Infection: A Systematic Review and Network Meta-analysis
Keywords: پاسخ پایدار ویروسی; Comparative Effectiveness; Mixed Treatment Comparison; NS5A Inhibitor; NS5B Inhibitor; CrI; credible interval; DAA; direct-acting antiviral; HCV; hepatitis C virus; MCMC; Markov Chain Monte Carlo; OR; odds ratio; RCT; randomized clinical trial; SVR; susta
Genome-Wide Association Study Identifies TLL1 Variant Associated With Development of Hepatocellular Carcinoma After Eradication of Hepatitis C Virus Infection
Keywords: پاسخ پایدار ویروسی; Genetics; Liver Cancer; Mutation; Metalloprotease; AFP; α-fetoprotein; anti-HBc; antibody to hepatitis B core antigen; BMP1; bone morphogenetic protein 1; CCl4; carbon tetrachloride; CDAA; choline-deficient L-amino acid-defined; CHC; chronic hepatitis C;
Finally, safe and effective treatment options for hepatitis C in hemodialysis patients
Keywords: پاسخ پایدار ویروسی; HCV; hepatitis C virus; ESRD; end-stage renal disease; HD; hemodialysis; DAA; direct acting antivirals, SOF, sofosbuvir; SIM; simeprevir; LED; ledipasvir; DCV; daclatasvir; RBV; ribavirn; IFN; interferon; SVR; sustained virologic response; pk; pharmacokin
Direct anti-HCV agents
Keywords: پاسخ پایدار ویروسی; Hepatitis C virus; Cure HCV; Sustained virologic response; Direct antiviral agents; NS3/4A protease inhibitor
Hepatitis C Virus Testing and Treatment Among Persons Receiving Buprenorphine in an Office-Based Program for Opioid Use Disorders
Keywords: پاسخ پایدار ویروسی; Ab; antibody; ALT; alanine transaminase; AST; aspartate transaminase; BMC; Boston Medical Center; DAA; directly acting antivirals; EMR; electronic medical record; ETR; end-treatment response; FDA; Food and Drug Administration; FIB-4; fibrosis-4; HIPAA; He
Research ArticleSustained virologic response of 100% in HCV genotype 1b patients with cirrhosis receiving ombitasvir/paritaprevir/r and dasabuvir for 12Â weeks
Keywords: پاسخ پایدار ویروسی; HCV; hepatitis C virus; GT; genotype; SVR; sustained virologic response; SVR12; sustained virologic response 12Â weeks post-treatment; PegIFN; pegylated interferon; RBV; ribavirin; DAA; direct-acting antiviral; OBV; ombitasvir; PTV; paritaprevir; r; riton
Sustained virologic response to interferon-free therapies ameliorates HCV-induced portal hypertension
Keywords: پاسخ پایدار ویروسی; HVPG; hepatic venous pressure gradient; ACLD; advanced chronic liver disease; HCV; hepatitis C virus; PegIFN/RBV; pegylated interferon and ribavirin; SVR; sustained virologic response; IFN; interferon; SOF; sofosbuvir; TE; transient elastography; BL; base
IFNL4 ss469415590 polymorphism contributes to treatment decisions in patients with chronic hepatitis C virus genotype 1b, but not 2a, infection
Keywords: پاسخ پایدار ویروسی; ALT; alanine aminotransferase; AST; aspartate aminotransferase; BMI; body mass index; cEVR; complete early virological response; CHC; chronic hepatitis C; CI; confidence interval; ETVR; end-of-treatment virological response; EVR; early virological respons
Research ArticleDaclatasvir plus simeprevir with or without ribavirin for the treatment of chronic hepatitis C virus genotype 1 infection
Keywords: پاسخ پایدار ویروسی; HCV; hepatitis C virus; SMV; simeprevir; PegIFN; peginterferon; RBV; ribavirin; DCV; daclatasvir; ASV; asuneprevir; SVR; sustained virologic response; LLOQ; lower limit of quantitation; AE; adverse event; SVR12; sustained virologic response at posttreatme
Adherence to ribavirin in chronic hepatitis C patients on antiviral treatment: Results from a randomized controlled trial using real-time medication monitoring
Keywords: پاسخ پایدار ویروسی; CHC; chronic hepatitis C; SMS; Short Message Service; RTMM; real-time medication monitoring; HCV; hepatitis C virus; SVR; sustained virologic response; PEG-interferon; pegylated interferon; AE; adverse event; EVR; early virologic response; WBC; white bloo
Research ArticleEfficacy and safety of ombitasvir/paritaprevir/r and dasabuvir compared to IFN-containing regimens in genotype 1 HCV patients: The MALACHITE-I/II trials
Keywords: پاسخ پایدار ویروسی; HCV; hepatitis C virus; GT; genotype; TPV; telaprevir; PegIFN; pegylated interferon; RBV; ribavirin; SVR; sustained virologic response; DAA; direct-acting antiviral agents; OBV; ombitasvir; PTV; paritaprevir; r; ritonavir; DSV; dasabuvir; IL28B; interleuk
Effects of Eradicating Hepatitis C Virus Infection in Patients With Cirrhosis Differ With Stage of Portal Hypertension
Keywords: پاسخ پایدار ویروسی; Esophagus; Bleeding; Long-Term Outcome; Portal Pressure; ALT; alanine-aminotransferase; DAA; direct-acting antivirals; EGS; esophageal gastroscopy; EV; esophageal varices; HCC; hepatocellular carcinoma; HCV; hepatitis C virus; LD; liver decompensation; LT
Effectiveness of Simeprevir Plus Sofosbuvir, With or Without Ribavirin, in Real-World Patients With HCV Genotype 1 Infection
Keywords: پاسخ پایدار ویروسی; Chronic Hepatitis; Direct-Acting Agent; NS3/4A Protease Inhibitor; NS5B; AASLD; American Association for the Study of Liver Disease; AE; adverse event; CI; confidence interval; FDA; Food and Drug Administration; HCV; hepatitis C virus; IDSA; Infectious Di
Safety and Effectiveness of Direct-Acting Antiviral Agents for Treatment of Patients With Chronic Hepatitis C Virus Infection and Cirrhosis
Keywords: پاسخ پایدار ویروسی; Chronic Hepatitis C; Direct-Acting Antivirals; Decompensation; Safety; CI; confidence interval; CP; Child-Pugh; DAA; direct-acting antiviral; HCC; hepatocellular carcinoma; HCV; hepatitis C virus; HR; hazard ratio; MELD; model for end-stage liver diseas